Public Release: 

Drug-resistant urinary tract infections spreading worldwide

Faculty of 1000

A sudden worldwide increase in an antibiotic-resistant bacterium is cause for concern, according to a review in f1000 Medicine Reports.

Faculty of 1000 member Dr Johann Pitout, of the Department of Pathology and Laboratory Medicine, University of Calgary, urges the medical community to monitor the spread of a multi-drug resistant bacterium before it becomes necessary to use more powerful antibiotics as a first response.

Extended-spectrum β-lactamases (ESBLs) are bacterially-produced enzymes that confer resistance to penicillin-type antibiotics. ESBLs have been commonly linked to nosocomial infections, which are generally treated with intravenously-administered antibiotics such as the carbapenems.

However, in recent years there has been a drastic increase in community-acquired infections, caused by a single strain of ESBL-producing E. coli. Dr Pitout suggests that the rapid spread of this particular strain is due, at least in part, to international travel through high-risk areas such as the Indian subcontinent.

Using carbapenems as the first response to such infections increases the risk of inducing resistance to them in the community, nullifying some of our most powerful anti-bacterial strategies. Dr Pitout recommends that the medical community should use existing methods to identify infections caused by ESBL-producing bacteria, and empirically test the efficacy of other antibiotics in treating community-acquired infections.

Dr Pitout concludes, "If this emerging public health threat is ignored ... the medical community may be forced to use the carbapenems as the first choice for the empirical treatment of serious [community-acquired UTIs]."


Notes to Editors

1. Dr Johann Pitout is a Faculty Member for f1000 Medicine, Infectious Diseases Section, and works at the Pathology and Laboratory Medicine, University of Calgary, Canada

2. The full text of this article is available for subscribers at

3. Faculty of 1000, which comprises and, is a unique online service that helps you stay informed of high impact articles and access the opinions of global leaders in medicine and biology. Our distinguished international faculty select and evaluate key articles across the sciences, providing a rapidly updated, authoritative guide to the literature.

4. Please name F1000 Medicine Reports and Faculty of 1000 Medicine in any story you write. If you are writing for the web, please link to the website (details below).

5. The F1000 Medicine Reports journal (ISSN 1757-5931), publishes short commentaries by expert clinicians focussing on the most important studies identified by Faculty of 1000 Medicine that are likely to change clinical practice. The commentaries summarise the implications of important new research findings for clinicians http://

6. Please contact Steve Pogonowski, PR Manager, for a complimentary journalist subscription to Faculty of 1000

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.